Yahoo Search Busca da Web

Resultado da Busca

  1. Há 5 dias · Abstract. e12582. Background: The goal of our study is to improve the diagnosis and treatment of DCIS through the identification of the factors driving its invasion and metastasis. Methods: We utilized the Mouse INtraDuctal (MIND) model to investigate the mechanism (s) by which some DCIS become invasive while others remain indolent.

  2. Há 3 dias · The main criteria for the unresectability of pancreatic ductal adenocarcinoma are the presence of metastasis and/or vascular invasion, particularly encasement of the celiac trunk and superior mesenteric artery.

    • adenocarcinoma in situ e invasor1
    • adenocarcinoma in situ e invasor2
    • adenocarcinoma in situ e invasor3
    • adenocarcinoma in situ e invasor4
    • adenocarcinoma in situ e invasor5
  3. Há 5 dias · Gastrointestinal Imaging. May 29, 2024. Imaging for Early Detection of Pancreatic Ductal Adenocarcinoma: Updates and Challenges in the Implementation of Screening and Surveillance Programs. Authors: Chenchan Huang, MD.

  4. Há 5 dias · e16320. Background: Treatment options for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) have historically been limited. FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) are both recommended first line (1L) treatments that have shown efficacy vs. gemcitabine monotherapy in clinical trials.

  5. Há 5 dias · e20083 Background: While immunohistochemistry (IHC) slides are commonly used to assess the presence of actionable biomarkers, the recent advances in artificial intelligence (AI) focus exclusively on hematoxylin and eosin (H&E) slides. Nonetheless, many IHC slides, potentially rich in prognostic information, remain underexplored for risk stratification and outcome prediction. Our study aims to ...

  6. Há 5 dias · People with two subtypes of adenocarcinoma of the lung, adenocarcinoma in situ and minimally invasive adenocarcinoma have a better outcome, especially when the cancer is treated early...

  7. Há 3 dias · This review discussed the potential of neoantigen-based immunotherapy for pancreatic ductal adenocarcinoma (PDAC). In this manuscript, the authors discussed the general concept of neoantigen and their role in PDAC's immunosuppressive and heterogeneous tumor microenvironment.